Biomodulin T
Sponsors
Center National of Bioproducts (BioCen), National Center of Bioproducts (BIOCEN), Centro Nacional de Biopreparados (BioCen), Centro Nacional de Biopreparados (BIOCEN), National Center for Bioproducts (BioCen).
Conditions
COVID-19
COVID-19
SARS-CoV2COVID-19 prevention
COVID-19
SARS-CoV2Human Immunodeficiency VirusImmune response in patients with CKD-5 on an iterated hemodialysis regimen
COVID-19
SARS-CoV2Prevention of infections, including covid-19
Covid-19
SARS-CoV2Prevention of infections including COVID-19
COVID-19
SARS-CoV2Septic shockThymus hypoplasia
Thymic Hypoplasia
Phase 3
Phase 4
Unknown Phase
Exploratory study of BMT EV to stimulate immune response in patients with CKD-5 on iterated hemodialysis
Active, not recruitingRPCEC00000316
Start: 2020-07-02Target: 20Updated: 2026-09-14
Biomodulina T - IM - covid-19 - older adult
Active, not recruitingRPCEC00000319
Start: 2020-04-13Target: 160Updated: 2026-09-14
Biomodulina T in pediatric septic shock. Exploratory study
Active, not recruitingRPCEC00000327
Start: 2020-10-01Target: 60Updated: 2026-09-14
Biomodulin T in older adult for protection in events of local transmission of COVID-19
Active, not recruitingRPCEC00000334
Start: 2020-09-14Updated: 2026-09-14
BIOMODULINA T in a long-lived population at high risk of COVID-19 infection
RecruitingRPCEC00000335
Start: 2020-09-26Updated: 2026-09-14
Biomodulin T-IM-oncological adults post chemotherapy-prevention COVID-19. Exploratory study
RecruitingRPCEC00000348
Start: 2021-04-22Target: 60Updated: 2026-09-14